menu search

Outlook Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Outlook Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
ISELIN, N.J., Dec. 23, 2022 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has entered into securities purchase agreements with existing institutional and accredited investors for the purchase and sale of […] The post Outlook Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market U... Read More
Posted: Dec 23 2022, 11:00
Author Name: forextv
Views: 102023

Search within

Pages Search Results: